Clinical Trial Update: Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating SGLT2 inhibitors for prevention of acute cardiorenal syndrome in congestive heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Snippet

Sponsor: I.M. Sechenov First Moscow State Medical University | Conditions: Congestive Heart Failure | Phase 4 | Status: COMPLETED